Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Transplant Infectious Disease
How do you dose maribavir in pediatric patients and on what is that based?
Related Questions
Do you treat non-albicans strains of Candida on sputum culture or BAL in patients who are immunosuppressed?
What is your preferred dosing of IV ganciclovir for CMV disease in immunocompromised patients?
Would you consider antifungal prophylaxis for immunocompromised patients with COVID-19 requiring mechanical ventilation, considering the high risk of invasive pulmonary aspergillosis in patients with severe COVID-19?
What is your preferred agent for fungal prophylaxis in a patient post lung transplant with abnormal LFTs?
Is the combination of a negative BAL PJP PCR and normal fungitell enough to rule out PJP pneumonia in an at-risk non-HIV patient?
Would you transition from IV to oral antibiotics in a solid organ transplant recipient with uncomplicated gram-negative bacteremia?
What are your top takeaways from ID Week 2024?
How long do you treat uncomplicated gram-negative rod bacteremia in solid organ transplant recipients?
Are you currently offering pemivibart (Pemgarda) for pre-exposure prophylaxis against COVID-19 to immunocompromised patients?
Do you manage antibacterials for enterococcal bacteremia differently in patients with severe immunosuppression?
